Business & Finance
Entest Group approves dividend of 3m common stock
11 May 2018 -

Entest Group Inc (OTC:ETNI) on Thursday declared its dividend of 3,000,000 of the common shares of Zander Therapeutics Inc on a pro rata basis.

The 3,000,000 of the common shares of Zander Therapeutics Inc, par value USD0.0001, are currently owned by Entest Group Inc.

Holders of record of the outstanding common shares of ETNI of the record date as of 30 May 2018 as well as the holders of record of the shares of any outstanding series of the preferred shares of ETNI of the record date as of 30 May 2018 shall receive one common share of Zander Therapeutics Inc for each 17 common and/or preferred shares of ETNI held as of the record date on the distribution date of 11 June 2018.

Zander Therapeutics is a subsidiary of Entest Group Inc (OTCPINK: ETNI), a publicly traded biotechnology company focused on veterinary medicine.

Login
Username:

Password: